Excess Length of Stay and Mortality Due to Clostridium Difficile Infection: a Multi-state Modelling Approach
Overview
Infectious Diseases
Affiliations
Background: The burden of healthcare-associated infections, such as healthcare-acquired Clostridium difficile (HA-CDI), can be expressed in terms of additional length of stay (LOS) and mortality. However, previous estimates have varied widely. Although some have considered time of infection onset (time-dependent bias), none considered the impact of severity of HA-CDI; this was the primary aim of this study.
Methods: The daily risk of in-hospital death or discharge was modelled using a Cox proportional hazards model, fitted to data on patients discharged in 2012 from a large English teaching hospital. We treated HA-CDI status as a time-dependent variable and adjusted for confounders. In addition, a multi-state model was developed to provide a clinically intuitive metric of delayed discharge associated with non-severe and severe HA-CDI respectively.
Findings: Data comprised 157 (including 48 severe) HA-CDI cases among 42,618 patients. HA-CDI reduced the daily discharge rate by nearly one-quarter [hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.61-0.84] and increased the in-hospital death rate by 75% compared with non-HA-CDI patients (HR: 1.75; 95% CI: 1.16-2.62). Whereas overall HA-CDI resulted in a mean excess LOS of about seven days (95% CI: 3.5-10.9), severe cases had an average excess LOS which was twice (∼11.6 days; 95% CI: 3.6-19.6) that of the non-severe cases (about five days; 95% CI: 1.1-9.5).
Conclusion: HA-CDI contributes to patients' expected LOS and risk of mortality. However, when quantifying the health and economic burden of hospital-onset of HA-CDI, the heterogeneity in the impact of HA-CDI should be accounted for.
Vintila B, Arseniu A, Morgovan C, Butuca A, Birlutiu V, Dobrea C Antibiotics (Basel). 2024; 13(2).
PMID: 38391530 PMC: 10885986. DOI: 10.3390/antibiotics13020144.
Economic Burden of Clostridioides difficile Infection in European Countries.
Reigadas E, Vazquez-Cuesta S, Bouza E Adv Exp Med Biol. 2024; 1435:1-12.
PMID: 38175468 DOI: 10.1007/978-3-031-42108-2_1.
Naylor N, Yamashita K, Iwami M, Kunisawa S, Mizuno S, Castro-Sanchez E Front Public Health. 2020; 8:562427.
PMID: 33330310 PMC: 7728661. DOI: 10.3389/fpubh.2020.562427.
Human α-Defensin-5 Efficiently Neutralizes Toxins TcdA, TcdB, and CDT.
Korbmacher M, Fischer S, Landenberger M, Papatheodorou P, Aktories K, Barth H Front Pharmacol. 2020; 11:1204.
PMID: 32903430 PMC: 7435013. DOI: 10.3389/fphar.2020.01204.
Kimura T, Stanhope S, Sugitani T Epidemiol Infect. 2020; 148:e65.
PMID: 32115019 PMC: 7118723. DOI: 10.1017/S0950268820000606.